Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
1.
Acta Gastroenterol Belg ; 85(3): 522-524, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35833908

RESUMO

Background: Hemophagocytic lymphohistiocytosis (HLH) is a life threatening condition caused by inappropriate immune activity. Infection is often the trigger, both in genetically predisposed and in sporadic cases. Although more commonly seen in the paediatric population, patients of all ages can be affected. Case presentation: A 26-year-old male patient with Crohn's disease, treated with ustekinumab, presented with high fever, epistaxis and anorexia. Laboratory results showed pancytopenia, and a high serum levels of ferritin and LDH. Colonoscopy revealed only mild signs of disease activity. CT-scan showed splenomegaly and multiple lymphadenopathies. Bone marrow aspirate was suggestive for hemophagocytosis. PCR & serology for parvovirus B19 came back positive. Treatment with ustekinumab was temporarily put on hold and supportive care was given. Viral replication decreased and he recovered completely. Conclusion: There is a known association between HLH and Crohn's disease. This is probably because they are more susceptible to infections with CMV, EBV and parvovirus B19, all known as triggers for HLH. The role of ustekinumab is unclear: did it play a role in the pathophysiological evolution of this primo-infection with parvovirus B19? On the other hand, did it contribute to the rather mild course of the disease, acting as a immunomodulator that works on interleukin-12, a cytokine that plays a role in HLH? Further study is warranted to answer these questions.


Assuntos
Doença de Crohn , Linfo-Histiocitose Hemofagocítica , Infecções por Parvoviridae , Parvovirus B19 Humano , Adulto , Criança , Doença de Crohn/complicações , Doença de Crohn/tratamento farmacológico , Citocinas , Ferritinas , Humanos , Interleucina-12 , Linfo-Histiocitose Hemofagocítica/diagnóstico , Linfo-Histiocitose Hemofagocítica/tratamento farmacológico , Linfo-Histiocitose Hemofagocítica/etiologia , Masculino , Infecções por Parvoviridae/complicações , Infecções por Parvoviridae/diagnóstico , Ustekinumab/uso terapêutico
2.
Acta Clin Belg ; 77(2): 470-483, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33635747

RESUMO

The Belgian Hematology Society (BHS) updated the 2013 guidelines for diagnosis and treatment of primary immune thrombocytopenia (ITP) [1]. As knowledge about ITP pathophysiology is increasing, the mode of action of old therapies is better understood and novel drugs are introduced to target more specific pathways.Corticosteroids with or without intravenous immunoglobulins (IgIV) remain the first-line treatment. According to the updated international guidelines a short course of corticosteroids rather than a prolonged treatment has to be recommended. The same guidelines stress that consequent therapies as thrombopoietic agents (TPO-RAs) and rituximab should be available independent of duration of ITP.Although the majority of recommendations is based on very low-quality evidence, it is strongly advised to individualize the ITP management taking patient values. and preferences in account. The main treatment goal in all ITP patients must be to maintain a safe platelet count to prevent or stop bleeding with a minimum of toxicity and not to normalize the platelet count.


Assuntos
Hematologia , Púrpura Trombocitopênica Idiopática , Adulto , Bélgica , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Púrpura Trombocitopênica Idiopática/tratamento farmacológico , Púrpura Trombocitopênica Idiopática/terapia , Rituximab/uso terapêutico
3.
Acta Clin Belg ; 70(1): 34-43, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25444072

RESUMO

OBJECTIVES: We evaluated azacitidine (Vidaza(®)) safety and efficacy in patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and chronic myelomonocytic leukaemia (CMML), in a real-life setting. Treatment response, dose, and schedule were assessed. METHODS: This non-interventional, post-marketing survey included 49/50 patients receiving azacitidine at 14 Belgian haematology centres from 2010-2012. Treatment-emergent adverse events (TEAEs), including treatment-related TEAEs, and serious TEAEs (TESAEs) were recorded throughout the study. Treatment response [complete response (CR), partial response (PR), haematological improvement (HI), stable disease (SD), treatment failure (TF)) and transfusion-independence (TI) were evaluated at completion of a 1-year observation period (1YOP) or at treatment discontinuation, and overall survival (OS), at study conclusion. RESULTS: The median age of patients was 74·7 (range: 43·9-87·8) years; 69·4% had MDS, 26·5% had primary or secondary AML, and 4·1% had CMML. Treatment-related TEAEs, grade 3-4 TEAEs, and TESAEs were reported in 67·3%, 28·6%, and 18·4% of patients, respectively. During 1YOP, patients received a median of 7 (1-12) treatment cycles. Treatment response was assessed for 38/49 patients. Among MDS and CMML patients (n = 29), 41·4% had CR, PR, or HI, 41·4% had SD, and 17·2% had TF. Among AML patients (n = 9), 44·4% had CR or PR, 33·3% had SD, and 22·2% had TF. TI was observed in 14/32 (43·8%) patients who were transfusion-dependent at baseline. Median (95% confidence interval) OS was 490 (326-555) days; 1-year OS estimate was 0·571 (0·422-0·696). CONCLUSIONS: Our data support previous findings that azacitidine has a clinically acceptable safety profile and shows efficacy.


Assuntos
Antimetabólitos Antineoplásicos/uso terapêutico , Azacitidina/uso terapêutico , Leucemia Mieloide Aguda/tratamento farmacológico , Leucemia Mielomonocítica Crônica/tratamento farmacológico , Síndromes Mielodisplásicas/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Antimetabólitos Antineoplásicos/efeitos adversos , Azacitidina/efeitos adversos , Bélgica/epidemiologia , Feminino , Humanos , Leucemia Mieloide Aguda/mortalidade , Leucemia Mielomonocítica Crônica/mortalidade , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/mortalidade , Vigilância de Produtos Comercializados , Resultado do Tratamento
4.
Curr Med Res Opin ; 31(1): 35-42, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25317956

RESUMO

OBJECTIVE: Azacitidine (Vidaza *) is approved in Europe for treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow (BM) blasts, and chronic myelomonocytic leukemia (CMML) with 10-29% BM blasts and no myeloproliferative syndrome (i.e. <13.000/µL white blood cells). In Belgium, the azacitidine reimbursement process can take several months, and is often delayed at submission for medical assessment by the Belgian National Institute for Health and Disability Insurance of incomplete patient dossiers, due to disease complexity and classification, and administrative burden. We describe the Vidaza Access Program and its application to an initial 175 patients. Individual medical dossiers were reviewed for completeness to facilitate patient access to treatment in Belgium. METHODS: A standardized anonymized patient information form is completed by the physician and sent for review to the Belgian Celgene Medical Department. The form is reviewed within three working days and, for complete dossiers, Celgene grants a financial guarantee for treatment with azacitidine. The patient can then be treated without the hospital being subjected to financial risk. RESULTS: Between January 2013 and June 2014, 63 physicians (53 Belgian hospitals) recruited 175 patients. In total, 163 patient dossiers were approved by Celgene (120 MDS, 36 AML, and 7 CMML), of which 104 dossiers were also approved by the review committee and 49 have been waiting for a final decision for a median of 6 months; no information is currently available for the remaining 10. No dossiers approved by Celgene have been rejected by the review committee. CONCLUSIONS: The Celgene Vidaza Access Program offers support to healthcare professionals in the appropriate use of azacitidine. By facilitating the assessment of patient dossiers and providing a financial guarantee for prescribers and hospitals, treatment can be initiated more rapidly and patients may better benefit from azacitidine treatment.


Assuntos
Antimetabólitos Antineoplásicos/uso terapêutico , Azacitidina/uso terapêutico , Acessibilidade aos Serviços de Saúde/organização & administração , Leucemia Mieloide Aguda/tratamento farmacológico , Leucemia Mielomonocítica Crônica/tratamento farmacológico , Síndromes Mielodisplásicas/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Bélgica , Feminino , Humanos , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mielomonocítica Crônica/diagnóstico , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/diagnóstico , Mecanismo de Reembolso/organização & administração
5.
Acta Clin Belg ; 70(1): 16-22, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25236359

RESUMO

OBJECTIVES: The efficacy and safety of plerixafor, an antagonist of the CXCR4 receptor, in combination with G-CSF has been demonstrated in patients suffering from Iymphoma and multiple myeloma (MM) eligible for autologous haematopoietic stem cell collection. However, different reimbursement criteria have been applied in different countries to select patients eligible for treatment with plerixafor. The objective of this observational study was to describe the plerixafor prescription modalities in daily practice in Belgium. METHODS: This open-label, prospective, observational study was conducted in 11 Belgian centres in 114 patients with lymphoma (Hodgkin's and non-Hodgkin's lymphoma) or MM who were treated with plerixafor according to the SmPC between April 2011 and October 2012. Patients included in another clinical trial with plerixafor were excluded from the study. RESULTS: The use of plerixafor in patients with MM or lymphoma was effective, with a success rate (defined as a total yield >2×10(6) CD34+ cells/kg) of 77%, and well tolerated (one SAE reported). Optimal collection (defined as a total yield >4×10(6) CD34+ cells/kg) was obtained for 43% of the study population (31% in lymphoma patients, compared to 61% in patients with MM). The use of plerixafor was in line with the SmPC and the Belgian reimbursement criteria for all patients. CONCLUSION: This study is showing that the use of plerixafor according to Belgian reimbursement criteria results in similar efficacy and safety as in other centres and countries worldwide.


Assuntos
Mobilização de Células-Tronco Hematopoéticas , Compostos Heterocíclicos/uso terapêutico , Padrões de Prática Médica , Adulto , Idoso , Bélgica , Benzilaminas , Ciclamos , Feminino , Humanos , Linfoma/terapia , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/terapia , Estudos Prospectivos , Transplante Autólogo
6.
Bone Marrow Transplant ; 49(7): 865-72, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24686988

RESUMO

Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.


Assuntos
Mobilização de Células-Tronco Hematopoéticas/métodos , Linfoma/terapia , Mieloma Múltiplo/terapia , Europa (Continente) , Humanos , Transplante Autólogo
7.
Ann Oncol ; 25(2): 447-54, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24478321

RESUMO

BACKGROUND: The main objective of this study was to assess preferences for involvement in treatment decisions and requests for prognostic information in newly diagnosed higher-risk myelodysplastic syndrome (MDS) patients. PATIENT AND METHODS: This was a prospective cohort observational study that consecutively enrolled MDS patients with an international prognostic scoring system (IPSS) risk category of intermediate-2 or high risk (summarized as 'higher risk'). The control preference scale was used to assess patient preferences for involvement in treatment decisions, and whether a request by patients for prognostic information during consultation was made, was also recorded. All of the patients were surveyed at the time of diagnosis before receiving treatment. Univariate and multivariate analyses were carried out to assess how sociodemographic, clinical and laboratory data related to decision-making preferences and requests for prognostic information. Relationship with the health-related quality of life (HRQOL) profile was also examined. RESULTS: A total of 280 patients were enrolled, 74% with intermediate-2 and 26% with high-risk IPSS. The mean age of patients was 70-year old (range: 32-89 years). One hundred thirty-two patients (47%) favored a passive role in treatment decision-making, whereas only 14% favored an active role. The remaining 39% of patients favored a shared decision-making approach. Patients with lower hemoglobin levels were more likely to prefer a passive role (P=0.037). HRQOL was generally better in patients preferring an active role versus those preferring a passive one. Overall, 61% (N=171) of patients requested prognostic information on survival during consultation. The likelihood of not requesting prognostic information was higher for older patients (P = 0.003) and for those with lower education (P=0.010). CONCLUSION: Decision-making preferences vary among patients with newly diagnosed higher-risk MDS. Current findings suggest that patients with worse underlying health conditions are more likely to prefer less involvement in treatment decisions.


Assuntos
Síndromes Mielodisplásicas/diagnóstico , Participação do Paciente/estatística & dados numéricos , Adulto , Idoso , Idoso de 80 Anos ou mais , Tomada de Decisões , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/epidemiologia , Síndromes Mielodisplásicas/terapia , Preferência do Paciente , Prevalência , Prognóstico , Estudos Prospectivos , Fatores Socioeconômicos , Resultado do Tratamento
8.
Acta Clin Belg ; 68(4): 253-62, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24455794

RESUMO

Myelodysplastic syndromes (MDS) represent a heterogeneous group of haematological disorders characterized by ineffective haematopoiesis and an increased risk for leukemic transformation. In recent years several new therapeutics have emerged that have demonstrated to alter the natural course of the disease. This document summarizes the state of the art in diagnosis and treatment of this heterogeneous disease, as proposed by a group of expert haematologists in the field of MDS from the Belgian Haematological Society. Its main purpose is to guide clinicians in daily practice to treat patients with this disease, within the limitations of current reimbursement modalities in Belgium.


Assuntos
Antineoplásicos/uso terapêutico , Quelantes/uso terapêutico , Hematínicos/uso terapêutico , Imunossupressores/uso terapêutico , Síndromes Mielodisplásicas/terapia , Azacitidina/uso terapêutico , Transfusão de Eritrócitos , Transplante de Células-Tronco Hematopoéticas , Humanos , Fatores Imunológicos/uso terapêutico , Ferro , Lenalidomida , Síndromes Mielodisplásicas/classificação , Síndromes Mielodisplásicas/diagnóstico , Talidomida/análogos & derivados , Talidomida/uso terapêutico
9.
Acta Clin Belg ; 67(3): 201-8, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22897069

RESUMO

The following recommendations, which aim at improving the clinical diagnosis ofTRALI and the laboratory investigations that can support it, were drawn up by a working group of the Superior Health Council. TRALI is a complication of blood transfusion that is both serious and underreported. Systematic reporting may help to develop preventive actions. Therefore, the Superior Health Council recommends that there should be a more stringent surveillance of patients who receive a blood component transfusion. The clinician should pay very close attention to any change in the patient's respiratory status (cf. dyspnoea and arterial desaturation), which should be notified systematically to the haemovigilance contact person in the hospital.


Assuntos
Lesão Pulmonar Aguda/diagnóstico , Lesão Pulmonar Aguda/terapia , Síndrome do Desconforto Respiratório/diagnóstico , Síndrome do Desconforto Respiratório/terapia , Reação Transfusional , Lesão Pulmonar Aguda/etiologia , Anticorpos Anticitoplasma de Neutrófilos/sangue , Autoanticorpos/sangue , Bélgica , Doadores de Sangue , Diagnóstico Diferencial , Antígenos HLA/imunologia , Humanos , Oxigenoterapia , Respiração com Pressão Positiva , Síndrome do Desconforto Respiratório/etiologia
10.
Eur J Clin Microbiol Infect Dis ; 31(6): 1173-9, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21971820

RESUMO

The purpose of this study was to evaluate efficacy and safety of voriconazole in patients with acute invasive aspergillosis (IA) in a real-life, clinical setting. This was a multicenter observational study in adult patients treated with voriconazole for invasive mycosis. The study evaluated clinical response, mortality, use of other licensed antifungal therapy (OLAT), and treatment duration. This sub-analysis evaluated treatment and outcome data specifically from adult patients with proven/probable IA, while safety data were assessed in patients with proven/probable/possible IA. Of the 141 patients enrolled, 113 were adults with proven/probable IA and six had possible IA. Voriconazole treatment duration ranged from 1 to 183 days (median, 49.5 days). Voriconazole was used exclusively in 64% (72/113) of patients and in combination/sequentially with OLAT in 36%. Overall successful treatment response was 50% (57/113 patients). Twelve percent (14/113) of patients were switched to OLAT, either because of insufficient response (four patients) or for safety reasons (10 patients). Overall and attributable (entirely or partially due to fungal infection) mortality rates were 52% (59/113) and 17%, respectively. Treatment-related adverse events were reported for 18% (22/119) of patients. This observational study confirms the results of previous clinical trials demonstrating voriconazole as an effective and safe agent for treatment of confirmed acute IA.


Assuntos
Antifúngicos/administração & dosagem , Antifúngicos/efeitos adversos , Aspergilose/tratamento farmacológico , Pirimidinas/administração & dosagem , Pirimidinas/efeitos adversos , Triazóis/administração & dosagem , Triazóis/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Aspergilose/mortalidade , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Análise de Sobrevida , Fatores de Tempo , Resultado do Tratamento , Voriconazol , Adulto Jovem
11.
Bone Marrow Transplant ; 47(8): 1046-50, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22080971

RESUMO

The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (>2.0 × 10(6) CD34+ cells/kg: 81.6%; >5.0 × 10(6) CD34+ cells/kg: 32.0%) than in NHL patients (>2.0 × 10(6) CD34+ cells/kg: 64.8%; >5.0 × 10(6) CD34+ cells/kg: 12.6%; P<0.0001) and also significantly higher in HL patients (>2.0 × 10(6) CD34+ cells/kg: 81.5%; >5.0 × 10(6) CD34+ cells/kg: 22.2%) than in NHL patients (P=0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.


Assuntos
Fármacos Anti-HIV/administração & dosagem , Mobilização de Células-Tronco Hematopoéticas/métodos , Transplante de Células-Tronco Hematopoéticas , Compostos Heterocíclicos/administração & dosagem , Doença de Hodgkin/terapia , Linfoma não Hodgkin/terapia , Mieloma Múltiplo/terapia , Adolescente , Adulto , Idoso , Benzilaminas , Remoção de Componentes Sanguíneos/métodos , Criança , Ciclamos , União Europeia , Feminino , Fator Estimulador de Colônias de Granulócitos , Doença de Hodgkin/sangue , Humanos , Contagem de Leucócitos , Linfoma não Hodgkin/sangue , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/sangue , Transplante Homólogo
13.
Acta Clin Belg ; 66(3): 200-4, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21837928

RESUMO

INTRODUCTION: Currently available stem cell mobilizing regimens (G-CSF +/- chemotherapy) show high failure rates, especially in heavily pretreated patients. Plerixafor, a new stem cell mobilizing agent blocking the CXCR4-SDF-1 interaction, offers a new strategy for stem cell mobilization, especially in poor mobilizers.This study reports on the outcome of the Belgian compassionate use program (CUP). MATERIALS AND METHODS: Between July 2008 and July 2009, 14 Belgian transplant centres participated in plerixafor CUP. In total, 22 poor stem cell mobilizers were included. Patients who previously failed stem cell mobilization received a combination of G-CSF (morning of Day 1-5) and plerixafor (evening of Day 4). Apheresis was performed on Day 5. G-CSF, plerixafor and apheresis were continued until at least 2 x 10(6)/kg CD34+ cells were obtained in a maximum of 3 collections. RESULTS: A mean of 2 plerixafor administrations was needed to reach > or = 2 x 10(6)/kg CD34+ cells. The overall cumulative success rate (defined as the proportion of patients achieving a successful collection after a maximum of 3 apheresis days) was 64%. Half of the heavily pretreated patients ( 3 prior chemotherapy regimens) could be mobilized successfully. Patients who received < or = 2 prior chemotherapy regimens mobilized successfully in 75% of the cases. Thirteen patients (59.1%) underwent autologous stem cell transplantation with normal neutrophil and platelet recovery times. CONCLUSION: For patients failing previous mobilization attempts, the combination of plerixafor and G-CSF is a successful mobilizing strategy, even in poor mobilizers who received > or = 3 prior chemotherapy regimens.


Assuntos
Ensaios de Uso Compassivo , Mobilização de Células-Tronco Hematopoéticas/métodos , Compostos Heterocíclicos/uso terapêutico , Doença de Hodgkin/tratamento farmacológico , Linfoma não Hodgkin/tratamento farmacológico , Mieloma Múltiplo/tratamento farmacológico , Receptores CXCR4/antagonistas & inibidores , Antígenos CD34/metabolismo , Benzilaminas , Contagem de Células , Ciclamos , Quimioterapia Combinada , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Compostos Heterocíclicos/administração & dosagem , Humanos
14.
Acta Clin Belg ; 64(5): 393-8, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19999386

RESUMO

OBJECTIVE: To perform an economic evaluation of voriconazole versus caspofungin in first line treatment of invasive aspergillosis (IA). These 2 antifungal drugs have a more favorable toxicity profile than the conventional amphotericin B and have a lower cost than the expensive liposomal/lipid formulation of amphotericin B. No head-to-head comparative study was conducted with voriconazole and caspofungin in IA. Based on the clinical trials of both antifungals, a conservative approach of similar efficacy has been considered. METHODS: The analysis is based on a simplified cost-minimization model with results from the National Health system RIZIV/INAMI perspective (year 2008). Only limited direct costs were considered, namely the drug cost over the episode of treatment.Treatment duration and patients' weight were key parameters. Their values were obtained from the Belgian observational VORIBEL study (Pfizer data on file) for voriconazole treatment. Treatment duration for caspofungin was derived from the EORTC study where almost 50% of the patients were recruited in Belgian centres. Mean cost and incremental cost were calculated. Univariate sensitivity analyses were carried out on weight, treatment duration as well as on route of administration. RESULTS: In invasive aspergillosis, the weighted cost per episode of fungal infection was 11.996 pound with voriconazole treatment (voriconazole IV followed by oral voriconazole) and 13.657 pound with caspofungin treatment (intravenous caspofungin only). The incremental saving with voriconazole treatment was 1.661 pound per patient.The cost-saving results of voriconazole were confirmed with varying treatment duration within realistic range. 41% of the patients in the VORIBEL study were fully treated with oral formulation. For these patients a saving of 6.375 pound was achieved with the use of oral voriconazole. CONCLUSION: Voriconazole is a cost-saving option compared with caspofungin in the treatment of invasive aspergillosis.


Assuntos
Antifúngicos/economia , Aspergilose/tratamento farmacológico , Custos de Medicamentos , Equinocandinas/economia , Pirimidinas/economia , Triazóis/economia , Antifúngicos/administração & dosagem , Antifúngicos/uso terapêutico , Bélgica , Peso Corporal , Caspofungina , Equinocandinas/administração & dosagem , Equinocandinas/uso terapêutico , Humanos , Lipopeptídeos , Pirimidinas/administração & dosagem , Pirimidinas/uso terapêutico , Triazóis/administração & dosagem , Triazóis/uso terapêutico , Voriconazol
16.
Acta Clin Belg ; 64(6): 517-9, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-20101875

RESUMO

We report a case of haemolytic due to the use of piperacillin-tazobactam in a 50-year-old woman. Since 2002 4 other cases were reported. Either the presence of piperacillin as tazobactam can induce haemolysis. In all cases discontinuating the drugs resolves the haemolysis. Although drug-induced haemolytic anaemia due to piperacillin-tazobactam is rare, the common use of this antibioticum in the critical care setting should alert the physician as a possible culprit in cases of haemolytic anaemia.


Assuntos
Anemia Hemolítica/induzido quimicamente , Antibacterianos/efeitos adversos , Transfusão de Sangue , Feminino , Humanos , Pessoa de Meia-Idade , Ácido Penicilânico/efeitos adversos , Ácido Penicilânico/análogos & derivados , Piperacilina/efeitos adversos , Combinação Piperacilina e Tazobactam
17.
Transpl Infect Dis ; 9(2): 126-31, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17461998

RESUMO

A hematopoietic stem cell transplant recipient developed a mucosal herpes simplex virus-1 (HSV-1) infection while under acyclovir (ACV) treatment (HSV was later shown to be resistant to ACV). Concomitantly, the patient presented a hemorrhagic cystitis (HC) due to polyomavirus BK, for which intravenous cidofovir (CDV) was prescribed. The patient benefited from the broad-spectrum anti-DNA virus activity of CDV, and not only the HC resolved without signs of nephrotoxicity but also the HSV-1 lesions disappeared. This is the first report describing the effect of CDV on 2 simultaneous and unrelated DNA viral infections in an immunosuppressed transplant recipient. In addition, we describe here that this HSV-1 isolate possesses a unique phenotype and genotype.


Assuntos
Aciclovir/uso terapêutico , Antivirais/uso terapêutico , Vírus BK , Transplante de Medula Óssea/efeitos adversos , Citosina/análogos & derivados , Herpes Simples/tratamento farmacológico , Herpesvirus Humano 1/isolamento & purificação , Organofosfonatos/uso terapêutico , Infecções por Polyomavirus/tratamento farmacológico , Infecções Tumorais por Vírus/tratamento farmacológico , Adolescente , Cidofovir , Citosina/uso terapêutico , Farmacorresistência Viral , Feminino , Herpes Simples/complicações , Humanos , Infecções por Polyomavirus/complicações , Infecções Tumorais por Vírus/complicações
18.
Acta Clin Belg ; 62(1): 36-47, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17451144

RESUMO

Recommendations aiming at standardising and rationalising clinical indications for the transfusion of platelets in Belgium were drawn up by a working group of the Superior Health Council. To this end the Superior Health Council organised an expert meeting devoted to "Guidelines for the transfusion of platelets" in collaboration with the Belgian Hematological Society. The experts discussed the indications for platelet transfusions, the ideal platelet concentrate and the optimal platelet transfusion therapy. The recommendations prepared by the experts were validated by the working group with the purpose of harmonising platelet transfusion in Belgian hospitals.


Assuntos
Transfusão de Plaquetas/normas , Guias de Prática Clínica como Assunto , Bélgica , Humanos
19.
Leukemia ; 19(10): 1768-73, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16079891

RESUMO

The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40 patients >60 years of age with acute myeloid leukemia (AML) who were not considered eligible for conventional chemotherapy because of advanced age or poor performance status. The drug was administered at the dose of 9 mg/m2 as a single 2-h i.v. infusion on days 1 and 15. Patients who achieved a complete remission (CR/CRp) were to receive a consolidation with two additional injections of the immunotoxin at the same dose. The overall CR/CRp rate was 17% (95% CI, 8-32%). The CR/CRp rate in patients 61-75 years old was 33% (6/18), and 5% (1/22) in patients older than 75 years. Induction death occurred in seven patients (17%), all aged above 75 years. Overall survival was significantly longer in patients aged 61-75 years than in older individuals (P=0.05), and in CD33+ cases than in CD33- cases (P=0.05). We conclude that the dose/schedule of gemtuzumab ozogamicin used in this trial is too toxic in the age group over 75 years. For these patients, additional studies with reduced doses of the immunotoxin are warranted.


Assuntos
Aminoglicosídeos/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Idoso Fragilizado , Imunotoxinas/uso terapêutico , Leucemia Mieloide/tratamento farmacológico , Doença Aguda , Idoso , Idoso de 80 Anos ou mais , Anticorpos Monoclonais Humanizados , Feminino , Gemtuzumab , Humanos , Leucemia Mieloide/classificação , Masculino , Pessoa de Meia-Idade , Indução de Remissão , Taxa de Sobrevida
20.
Acta Clin Belg ; 60(2): 102-5, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16082997

RESUMO

Therapy of systemic lupus erythematosus (SLE) with major organ involvement consists of aggressive immunosuppression with glucocorticoids and cytotoxic agents. When remission is achieved, maintenance therapy is begun to reduce the risk of relapse while minimizing toxicity. Remission with standard therapy is, however, not always achieved. We discribe a women with SLE and microangiopathic haemolytic anaemia and thrombocytopenia, pneumonitis and nephritis refractory to high-dose steroids, pulse cyclophosphamide, plasmapheresis and intravenous immunoglobulins. The anti-CD20 monoclonal antibody rituximab was administered, resulting in major clinical and biochemical improvement. Therapy-resistant SLE generally has an ominous prognosis. A few anecdotal reports and small open studies describe beneficial effects of rituximab in these cases. Rituximab may be a promising new approach to improve the dismal outcome of therapy-resistant SLE.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Antineoplásicos/uso terapêutico , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Terapia de Salvação , Adulto , Anticorpos Monoclonais Murinos , Terapia Combinada , Relação Dose-Resposta a Droga , Esquema de Medicação , Resistência a Múltiplos Medicamentos , Feminino , Seguimentos , Humanos , Medição de Risco , Rituximab , Índice de Gravidade de Doença , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...